Damora Therapeutics
DMRA
21 hedge funds and large institutions have $2.77M invested in Damora Therapeutics in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 4 closing their positions.
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
5.89% less ownership
Funds ownership: 20.09% → 14.2% (-5.9%)
29% less capital invested
Capital invested by funds: $3.92M → $2.77M (-$1.15M)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$124K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$59.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$44.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$665K |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$646K |
| 3 |
LCM
Laurion Capital Management
New York
|
-$63.7K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$30.8K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$12.5K |
DMRA Hedge Fund Activity: Q4 2023 in Review
21 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q4 2023, worth a combined $2.77M — down 29% from $3.92M a quarter earlier.
Fund positioning in DMRA was balanced in Q4 2023: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 8 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $124K. The largest seller was OrbiMed, exiting entirely with an estimated $665K sold.
- 21 institutional investors held Damora Therapeutics (DMRA) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $2.77M of Damora Therapeutics stock for Q4 2023, down 29% quarter-over-quarter.
- 4 funds opened new Damora Therapeutics positions in Q4 2023 and 4 closed out, a net change of 0 holders.
- The largest Damora Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $124K added.
- The largest Damora Therapeutics seller in Q4 2023 was OrbiMed, an estimated $665K sold.
Based on aggregated 13F filings for Q4 2023.